Ken Griffin Exelixis, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $570,960 - $717,600	26,000 Added 28.54%	117,100 $3.04 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $42,714 - $49,833	-2,100 Reduced 2.25%	91,100 $2.05 Million
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $943,956 - $1.12 Million	-46,800 Reduced 33.43%	93,200 $2.21 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $227,150 - $284,734	-11,800 Reduced 7.77%	140,000 $3.36 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $1.43 Million - $1.71 Million	75,200 Added 98.17%	151,800 $3.32 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $468,786 - $528,384	-25,800 Reduced 25.2%	76,600 $1.46 Million
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $502,040 - $597,828	-30,800 Reduced 23.12%	102,400 $1.99 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $83,776 - $97,384	5,600 Added 4.39%	133,200 $2.14 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $83,104 - $118,031	-5,300 Reduced 3.99%	127,600 $2 Million

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.